Med-Polonia Sp. z o.o.

Poznan, Greater Poland Voivodeship 60-693

4 studies enrolling now · 10 studies all time

What they study most

Breast Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Hepatocellular Carcinoma, Locally Advanced Renal Cell Carcinoma, Locally Advanced Urothelial Cancer, Metastatic Clear-Cell Renal Cell Carcinoma, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Metastatic Urothelial Cancer, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer

Studies at this site

• A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) — Recruiting now
• This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. — Recruiting now
• A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% — Recruiting now
• A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) — Recruiting now
• A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma — Running, not enrolling
• A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity — Running, not enrolling
• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) — Completed
• A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) — Completed
• Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET — Completed